Bioventus Inc.·Healthcare

Check-Cap (NASDAQ: MBAI - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Insider and Institutional Ownership 1.1% of Check-Cap shares are

Biosig Technologies (NASDAQ: STEX - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Volatility and Risk Biosig Technologies has a beta

Bioventus (NASDAQ: BVS) executives told investors the company closed 2025 with what leadership described as a "solid quarter" and a "pivotal year," highlighting stronger organic growth, higher profitability, and record quarterly operating cash flow while laying out a 2026 plan to step up investment in several growth initiatives. Fourth-quarter performance and mix For the fourth quarter,

Bioventus Inc. (NASDAQ: BVS - Get Free Report)'s share price gapped up prior to trading on Thursday after Cantor Fitzgerald upgraded the stock to a strong-buy rating. The stock had previously closed at $8.47, but opened at $9.00. Bioventus shares last traded at $9.27, with a volume of 295,205 shares. BVS has been the subject of

Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 million increased 97% 2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generation DURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2025, and provided its financial guidance for full-year 2026.
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Healthcare
Medical - Devices
930
2021-02-11
0.69